Efficacy, Compliance And Toxicity Factors Are Affecting The Rate Of Normalization Of Body Iron Stores In Thalassemia Patients Using The Deferiprone And Deferoxamine Combination Therapy

The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores

(2010) J. C. Wood et al.   BLOOD

Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy

(2010) Annita Kolnagou et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities

(2010) George J Kontoghiorghes   Expert Opinion On Drug Safety

Safety issues of iron chelation therapy in patients with normal range iron stores including thalassaemia, neurodegenerative, renal and infectious diseases

(2010) G J Kontoghiorghes et al.   Expert Opinion On Drug Safety

Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging

(2010) A. Pepe et al.   HAEMATOLOGICA

Maintenance of Normal Range Body Iron Store Levels for up to 4.5 Years in Thalassemia Major Patients Using Deferiprone Monotherapy

(2010) Annita Kolnagou et al.   HEMOGLOBIN

Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major

(2009) Kallistheni Farmaki et al.   BRITISH JOURNAL OF HAEMATOLOGY

A New Era in Iron Chelation Therapy: The Design of Optimal, Individually Adjusted Iron Chelation Therapies for the Complete Removal of Iron Overload in Thalassemia and other Chronically Transfused Patients

(2009) George J. Kontoghiorghes   HEMOGLOBIN

Uses and Limitations of Serum Ferritin, Magnetic Resonance Imaging T2 and T2* in the Diagnosis of Iron Overload and in the Ferrikinetics of Normalization of the Iron Stores in Thalassemia Using the International Committee on Chelation Deferiprone/Deferoxamine Combination Protocol

(2009) Anita Kolnagou et al.   HEMOGLOBIN

Myocyte Damage and Loss of Myofibers is the Potential Mechanism of Iron Overload Toxicity in Congestive Cardiac Failure in Thalassemia. Complete Reversal of the Cardiomyopathy and Normalization of Iron Load by Deferiprone

(2008) Annita Kolnagou et al.   HEMOGLOBIN

Long Term Comparative Studies in Thalassemia Patients Treated with Deferoxamine or a Deferoxamine/Deferiprone Combination. Identification of Effective Chelation Therapy Protocols

(2008) Annita Kolnagou et al.   HEMOGLOBIN

Regression of symptoms after selective iron chelation therapy in a case of neurodegeneration with brain iron accumulation

(2008) Gian Luca Forni et al.   MOVEMENT DISORDERS